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Abstract
PDE9 inhibitors show potential for treatment of diseases such as diabetes. To help with discovery of PDE9 inhibitors, we
performed mutagenesis, kinetic, crystallographic, and molecular dynamics analyses on the active site residues of Gln453 and
its stabilizing partner Glu406. The crystal structures of the PDE9 Q453E mutant (PDE9Q453E) in complex with inhibitors
IBMX and (S)-BAY73-6691 showed asymmetric binding of the inhibitors in two subunits of the PDE9Q453E dimer and also
the significant positional change of the M-loop at the active site. The kinetic analysis of the Q453E and E406A mutants
suggested that the invariant glutamine is critical for binding of substrates and inhibitors, but is unlikely to play a key role in
the differentiation between substrates of cGMP and cAMP. The molecular dynamics simulations suggest that residue Glu406
may be protonated and may thus explain the hydrogen bond distance between two side chain oxygens of Glu453 and
Glu406 in the crystal structure of the PDE9Q453E mutant. The information from these studies may be useful for design of
PDE9 inhibitors.
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Introduction
Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze the
second messengers cAMP and cGMP, and play crucial roles in
many physiological processes. Twenty one of the human PDE
genes encode about a hundred of PDE proteins that are
categorized into eleven families on the basis of their biochemical
and pharmacological properties [1–3]. PDE inhibitors have been
widely studied as therapeutics for treatment of various diseases [4–
9]. A well known example is the PDE5 selective inhibitor sildenafil
that has been used for the treatment of male erectile dysfunction
and pulmonary hypertension [4,10]. Selective inhibitors of PDE9
have demonstrated potentials for treatment of human diseases,
including insulin-resistance syndrome and diabetes [11,12],
cardiovascular diseases [13], obesity [14], and neurodegenerative
disorders such as Alzheimer’s disease [15–16].
PDE molecules contain an N-terminal regulatory domain and
a conserved catalytic domain at the C-terminus. Individual PDE
families display a preference for hydrolysis of the substrates
cAMP (PDE4, 7, 8), cGMP (PDE5, 6, 9), or both (PDE1, 2, 3, 10,
11) [1–3,17]. It has been a puzzle how the conserved active sites
of PDEs selectively recognize the subtle differences between
cAMP and cGMP. On the basis of the different conformations of
the invariant glutamine in the crystal structures, a mechanism
called ‘‘glutamine switch’’ was proposed for differentiation of the
substrates by PDEs [18]. However, this hypothesis was challenged
by the mutagenesis experiment [19] and the structural studies
[20–22].
To understand the roles of the invariant glutamine, we mutated
Gln453 of PDE9A2 to glutamic acid (PDE9Q453E) and its
stabilizing residue Glu406 to alanine, and measured the kinetic
parameters of the mutants. In addition, we performed molecular
dynamics (MD) simulations on the mutants and determined the
crystal structures of PDE9Q453E in complex with the inhibitors 3-
isobutyl-1-methylxanthine (IBMX) and (S)-BAY73-6691 (Fig. 1).
Our studies reveal the structural asymmetry of PDE9 and
potential protonation state of Glu406, and also suggest that
Gln453 is unlikely to play a key role in differentiation of the
substrates.
Materials and Methods
Molecular cloning, site-directed mutagenesis, and
protein expression
The catalytic domain of the wild type human PDE9A2
(GenBank number BC009047) was subcloned to vector pET15b
by following the protocol described previously [23]. The coding
region for residues 181-506 of PDE9A2 was amplified by PCR.
The amplified PDE9A2 cDNA and the expression vector pET15b
were digested by the restriction enzymes NdeI and XhoI, purified
by agarose gel electrophoresis, and then ligated together by T4
DNA ligase. The recombinant plasmid was selected by ampicillin
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site-directed mutagenesis kit (Stratagene, USA) was used to
generate the PDE9A2 mutants of Q453E and E406A. The
methylated parental plasmid was digested by DpnI endonuclease.
The mutations were verified by DNA sequencing.
The wild type and mutants of the PDE9A2 catalytic domain
were purified by using the similar protocols previously reported
[24]. In brief, the recombinant plasmid was transferred into E. coli
strain BL21 (Codonplus, Stratagene). The E. coli cells carrying the
pET-PDE9A2 plasmids were grown in LB medium at 37uCt o
absorption A600=,0.7 and then 0.1 mM isopropyl b-D-
thiogalactopyranoside was added to induce expression. The cells
after induction were grown at 15uC overnight. Recombinant
PDE9A2 proteins were purified by column chromatography of Ni-
NTA affinity (Qiagen), Q-Sepharose ion-exchanging (GE Health-
care), and Sephacryl S300 gel filtration (GE Healthcare). A typical
batch of purification yielded 20–100 mg PDE9A2 from a 2-liter
cell culture. The PDE9A2 proteins had purity greater than 95%,
as shown by SDS-PAGE.
Enzymatic assay
The enzymatic activities of the wild type PDE9A2 and its
mutants were assayed by using cAMP and cGMP as substrates. A
100 ml reaction mixture contained 50 mM Tris-HCl pH 8.2,
10 mM MgCl2, 0.5 mM DTT, 174 nM
3H-cAMP or 30 nM
3H-
cGMP (30,000–100,000 cpm, GE Healthcare), and various
concentrations of cAMP or cGMP. Each measurement was
repeated two times. The reaction was carried out at room
temperature for 15 min and then terminated by the addition of
0.2 M ZnSO4 and 0.2 M Ba(OH)2. The reaction product
3H-
AMP or
3H-GMP was precipitated by BaSO4, whereas unreacted
3H-cAMP or
3H-cGMP remained in the supernatant. Radioac-
tivity in the supernatant was measured in 2.5 ml Ultima Gold
liquid scintillation cocktails (PerkinElmer) by a PerkinElmer 2910
liquid scintillation counter. Vmax and KM values were calculated
by nonlinear regression on the curve of velocity versus substrate
concentration and also by Eadie-Hofstee plot. For the measure-
ment of IC50 of inhibitors, nine concentrations of inhibitors,
30 nM
3H-cGMP, and the enzyme concentration that hydrolyzed
up to 70% of the substrate were used. The inhibitors IBMX, (S)-
BAY73-6691, and zaprinast were purchased from Sigma-Aldrich.
The IC50 values were calculated by nonlinear regression.
Crystallization and structure determination
The catalytic domain of the PDE9Q453E mutant (10–15 mg/
mL, amino acids 181–506) was stored in a buffer of 50 mM NaCl,
20 mM Tris.HCl pH 7.5, 1 mM b-mercaptoethanol, and 1 mM
EDTA. After mixing with 2 mM IBMX, the PDE9Q453E-IBMX
complex was crystallized by hanging drop vapor diffusion against
the well buffer of 2.0 M Na formate, 0.1 M HEPES pH 7.5, 5%
xylitol at 4uC. Crystals of the PDE9Q453E-(S)-BAY73-6691
complex were prepared by soaking PDE9Q453E-IBMX co-
crystals in the crystallization buffer plus 2 mM (S)-BAY73-6691
at 25uC for 3 days. The crystals were flash-frozen in liquid
nitrogen by using the well buffer containing saturated xylitol as the
cryosolvent. X-ray diffraction data were collected at 100 K on
Beamline BL17U of Shanghai Synchrotron Radiation Facility,
China (Table 1) and processed by HKL2000 [25]. The structures
of the PDE9Q453E mutant in complex with IBMX and (S)-
BAY73-6691 were solved by the molecular replacement program
AMoRe [26], using the PDE9A2 catalytic domain [23] as the
initial model. The atomic model was rebuilt by program O [27] or
COOT [28] against the electron density maps that were improved
by the density modification package of CCP4. The structures were
refined by CNS [29] and REFMAC [30]. The atomic coordinates
and structure factors have been deposited into the Protein Data
Bank with accession numbers of 3QI3 and 3QI4.
Molecular dynamics simulations
The crystal structures of the wild type PDE9A2 in complex with
(R)- or (S)-BAY73-6691 (PDB access codes of 3K3E and 3K3H)
[24] and of the Q453E mutant in complex with (S)-BAY73-6691
(this study) were used to generate the PDE9A2 monomers for the
MD simulations. The hydrogen atoms were added by software
Sybyl 7.3.5. The protocol of the restricted electrostatic potential
fitting, as implemented in the Antechamber module of the
Figure 1. Chemical formulas of PDE9 inhibitors. 1-(2-chlorophe-
nyl)-6-(3,3,3-trifluoro-2-methylpropyl)-1H-pyrazolo [3,4-d]pyrimidin-
4(5H)-one (BAY73-6691) and 3-isobutyl-1-methylxanthine (IBMX).
doi:10.1371/journal.pone.0018092.g001
Table 1. Statistics on diffraction data and structure
refinement.
Data collection
PDE9A2(Q453E)-(S)-BAY73-
6691
PDE9A2(Q453E)-
IBMX
Space group P41212P 4 1212
Unit cell (a, c,A ˚) 103.1, 270.4 103.4, 270.0
Resolution (A ˚) 2.3 2.5
Total measurements 382,636 665,895
Unique reflections 63,252 50,388
Completeness (%) 95.8 (67.3)* 97.6 (72.5)*
Average I/s 14.5 (2.3)* 12.2 (6.2)*
Rmerge 0.092 (0.54)* 0.094 (0.24)*
Structure Refinement
R-factor 0.222 0.213
R-free 0.242 (10.0%){ 0.239 (10.0%){
Resolution (A ˚) 15-2.3 15-2.5
Reflections 58,317 48,879
RMS deviation for
Bond (A ˚) 0.007 0.007
Angle 1.2u 1.2u
Average B-factor (A ˚)
Protein 49.3 (5372)1 39.9 (5372)
Inhibitor 64.1 (48) 49.5 (48)
Zn 61.0 (2) 61.9 (2)
Mg 46.2 (2) 45.5 (2)
Water 43.8 (23) 42.1 (29)
*The numbers in parentheses are for the highest resolution shell.
{The percentage of reflections omitted for calculation of R-free.
1The number of atoms in the crystallographic asymmetric unit.
doi:10.1371/journal.pone.0018092.t001
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atomic charges of (R)- or (S)-BAY73-6691 at the ab initio HF/6-
31G* level. The Zn
2+ and Mg
2+ ions were treated by the non-
bonded method [32]. The bridging ligand between the two metal
ions was set as HO
2, as previously proposed [33]. The parameters
of the AMBER general force field (GAFF) and ff03 were used for
PDE9A2 and (R)-/(S)-BAY73-6691 [34]. The PDE9A2 complexes
were neutralized by adding sodium counter ions and solvated with
water molecules within 10 A ˚ radius to protein atoms.
The structures were first minimized for 6000 steps to remove
possible steric stress. The relaxed structures were gradually heated
from 0 to 300 K in 100 ps increments and then equilibrated for
200 ps at 300 K using the NVT (number of particles, volume, and
temperature) ensemble. Weak constraints of 10 and 2 kcal N mol
21
N A ˚ 22 were applied on the proteins during the heating and
equilibrating procedures, respectively. Finally, periodic boundary
dynamics simulations of 8 ns were carried out by using the NPT
(number of particles, pressure, and temperature) ensemble at 1
atm and 300 K. The SHAKE algorithm [35] was turned on for
the covalent bonds involved in hydrogen atoms with a tolerance of
1610
25 A ˚. The simple harmonic motion was applied to other
covalent bonds. The Particle-Mesh-Ewald method [36] was
applied to treat the long range electrostatic interactions with a
10 A ˚ non-bonded cutoff.
Results
Subtle conformational changes in the PDE9Q453E
structures
The crystallographic asymmetric unit of the PDE9Q453E
mutant in complex with IBMX or (S)-BAY73-6691 contains two
molecules of the PDE9A2 catalytic domain. A monomer of the
PDE9Q453E mutant is composed of 16 helices (Fig. 2A) that are
folded into a similar topology as PDE9 and other PDE families
[17]. The Q453E mutation did not significantly change the overall
structure, as shown by the small root-mean squared deviations
(RMSD) of 0.17 and 0.28 A ˚ for the superposition of Ca atoms of
the corresponding chains (A over A and B over B) between the
mutant and the wild type enzyme [23,24]. However, the side chain
of Glu453 showed significant conformational change due to the
mutation. In the wild type PDE9A2, the side chain of Gln453 was
stabilized by a hydrogen bond (2.8 A ˚) between NE2 of Gln453
and OE1 of Glu406. In the Q453E mutant structure, the side
chain of Glu453 rotated about 15u (Fig. 2B). This movement made
a distance of 3.8 A ˚ from OE2 of Glu453 to O4 of (S)-BAY73-6691,
and 3.2 A ˚ to OE1 of Glu406. The 3.2 A ˚ distance between two
electron-rich oxygen atoms may cause energetically unfavored
repulsion. A possible explanation may be that Glu406 is
protonated, as discussed in the section on MD simulations.
Asymmetry of the inhibitor binding and the PDE9 dimer
The major force for the IBMX binding to the active site of the
PDE9Q453E mutant was the hydrogen bond between N7 of
IBMX and OE1 of Glu453 and the stack of the xanthine ring of
IBMX against Phe456 (Fig. 3A). This feature is conserved in both
chains A and B and is similar to the IBMX binding in the wild type
PDE9A2. However, IBMX binding showed certain characteristics
of asymmetry in chains A and B of the PDE9Q453E dimer. First,
the conformation of IBMX was defined by the clear electron
density in chain B, but was less definite in chain A (Fig. S1). The B-
factors were 58 and 41 A ˚ 2, respectively for IBMXs in chains A and
B, indicating relatively lower occupancy of IBMX in chain A.
Second, two IBMXs showed a positional difference of about one
Angstrom, as revealed by the superposition between chains A and
B, in spite of the conservation of their stack against Phe456 and
interaction with the common PDE9A2 residues (Fig. 3A). Finally,
the N3 atom of IBMX in chain B formed a hydrogen bond with
OH of Tyr424 (3.2 A ˚), whereas the same interaction in chain A
shows a distance of 3.6 A ˚, which belongs to a typical polar
interaction (Fig. 3A).
The asymmetry is also observed in the binding of inhibitor (S)-
BAY73-6691 to the PDE9Q453E mutant. In the PDE9Q453E-
Figure 2. Structures of the PDE9Q453E mutant in complex with (S)-BAY73-6691. (A) Ribbon presentation of superposition of the wild type
PDE9A2 (green) over the PDE5Q453E mutant (purple) in complex with (S)-BAY73-6691 (golden balls). (B) Conformational change of Glu453 in the
PDE9Q453E mutant. The side chain of Glu453 rotated by about 15u to relieve the repulsion between electron-rich oxygens of Glu453 and (S)-BAY73-
6691. The residues of the wild type PDE9A2 and the PDE9Q453E mutant are presented in purple and golden colors, respectively.
doi:10.1371/journal.pone.0018092.g002
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BAY73-6691 to chain A was clearly defined by the electron density
maps of (2Fo - Fc) and (Fo - Fc) (Fig. S1). However, the electron
density in chain B had the quality only to reveal the binding
location but not the accurate conformation of the inhibitor. The B-
factor of (S)-BAY73-6691 in chain A (56 A ˚ 2) is significantly smaller
than that in chain B (72 A ˚ 2), consistent with the observation of low
occupancy of (S)-BAY73-6691 in china B. The interaction of (S)-
BAY73-6691 with chains A and B in the PDE9Q453E dimer is
very different. In chain A, the pyrazolo-pyrimidine ring of (S)-
BAY73-6691 stacked against the phenyl ring of Phe456 and its N5
atom formed a hydrogen bond with OE1 of Glu453 (Fig. 3B). In
chain B, (S)-BAY73-6691 formed no hydrogen bond with Glu453,
but with Tyr424 (Fig. 3B), although its pyrazolo-pyrimidine ring
remained stacked against Phe456.
While the biological implication of the asymmetric binding of
IBMX and (S)-BAY73-6691 in the PDE9Q453E structures is
unclear, it appears to be the consequence of the structural
asymmetry of two subunits in the PDE9Q453E dimer. Indeed, the
structural superposition between chains A and B yielded RMSDs
of 0.64 and 0.77 A ˚, respectively for the structures of PDE9Q453E-
IBMX and PDE9Q453E-(S)-BAY73-6691. These values are 2–3
times the RMSDs resulting from the comparison of the same
subunits between the wild type PDE9 and its mutants (A versus A
and B versus B). Detailed examination showed significant
positional changes around residues 440–450 that have differences
2 to 3 times the overall average for the Ca atoms (Fig. 3C). This
fragment is known as the M-loop in the PDE families, which is a
component of the active site and has been implicated to play
important roles in catalysis [37]. Since the M-loop also shows the
positional differences in the structures of the wild type PDE9A in
complex with substrate cGMP or inhibitors [22–24], the
asymmetry might have implications for design of PDE9 inhibitors.
The impact of Q453E and E406A mutations on the
enzymatic properties
The PDE9Q453E mutant had the KM values of 2.8 mM for
cGMP and 1.2 mM for cAMP, which represent about 25- and 2.5-
fold loss in comparison with the apparent affinity of the wild type
enzyme [23]. The catalytic activities of the PDE9Q453E mutant
toward cGMP and cAMP were also reduced to about half of those
of the wild type enzyme (Table 2). Thus, the Q453E mutation
caused a loss of about 50- and 5-folds of enzymatic efficacy, kcat/
KM, for cGMP and cAMP, respectively. The reduction of the
enzymatic efficacy for cGMP might be interpreted by the fact that
the Q453E mutation abolishes the hydrogen bond between NE2
of Gln453 and O6 of cGMP. However, the interpretation of the
loss of cAMP activity is unclear because the Q453E mutation
would be predicted not to change the number of hydrogen bond
with cAMP and thus the activity.
The E406A mutation reduced the apparent affinity and the
catalytic activity of cGMP by only 2-fold (Table 2). The E406A
mutation did not significantly change the affinity for cAMP, but
decreased the catalytic activity by about 8-fold (Table 2). In the
crystal structure of the wild type PDE9A2, Glu406 stabilizes the
side chain conformation of Gln453 with a hydrogen bond [22–24].
The E406A mutation will abolish this hydrogen bond and thus
presumably allow the side chain of Gln453 to rotate. As a result,
Figure 3. Asymmetric binding of the inhibitors to the active site of the PDE9Q453E mutant. (A) Interactions of IBMX with the residues in
subunit A (green sticks) and subunit B (golden). IBMX forms an additional hydrogen bond (dotted lines) with Tyr424 in subunit B, but not in subunit
A. (B) Superposition of the interactions of (S)-BAY73-6691 with the residues in subunit A (green and red sticks) and subunit B (golden and purple). (C)
Positional changes of the M-loop at the active site of the PDE9Q453E mutant. Subunit A is shown in cyan and golden colors while green and salmon
are for subunit B.
doi:10.1371/journal.pone.0018092.g003
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Gln453 after the rotation and the E406A mutant would thus be
expected to have increased cAMP activity. However, no significant
change on the apparent affinity (KM) for cAMP, but reduction of
kcat might imply that the Gln453 side chain does not rotate in the
E406A mutant. Thus, our kinetic study provides new evidence
against the mechanism of the ‘‘glutamine switch’’, in which
Gln453 is assumed to rotate for the recognition of substrate cGMP
or cAMP.
Regarding the inhibitor binding, the Q453E mutation led to a
minor loss in the affinity of IBMX and zaprinast (Table 3), but
showed a radical impact on (S)-BAY73-6691. The IC50 value of
(S)-BAY73-6691 for the PDE9Q453E mutant was .160 mM,
which is .1800 fold to IC50 of 86 nM for the wild type enzyme. A
possible interpretation to the different affinity of the inhibitors
might be ascribed to the binding modes among these inhibitors.
The non-selective and weak inhibitors IBMX and zaprinast are
relatively small and may adopt different orientations in the large
PDE9 binding pocket to result in a similar affinity in both wild
type and mutant enzymes. However, since the selective PDE9
inhibitor (S)-BAY73-6691 fits tightly to the binding pocket, the
Q453E mutation would cause a net loss of the hydrogen bond and
thus impact on the binding affinity. On the other hand, the E406A
mutation did not significantly alter the affinity of the three
inhibitors (Table 3). This may be understandable because Glu406
does not directly interact with the inhibitors.
Glu406 is likely protonated in the PDE9Q453E structure
as shown by MD simulations
To further understand the role of Gln453, we performed MD
simulations on the mutants PDE9Q453E and PDE9E406A.
Initially, the known structures of the wild type PDE9A2 in
complex with (R)-/(S)-BAY73-6691 were used to tune the
program for MD simulations. After a 4 ns MD run, stable
trajectories with RMSD of ,2A ˚ were obtained. The average
distances from NE2 and OE1 of Gln453 to O4 and N5 of (S)-
BAY73-6691 are 2.9 and 2.8 A ˚ in the MD model (Fig. S2), which
compares well with the distances of 2.9 and 2.7 A ˚ in the crystal
structure. In addition, the pyrazolo-pyrimidine ring of (S)-BAY73-
6691 remained stacked against Phe456 in the entire MD
trajectories. Since the hydrogen bond with the invariant glutamine
and the stack against phenylalanine are two key characteristics of
inhibitor binding in almost all PDE structures [17], the MD
simulations apparently simulate the crystal structures well.
Under the same conditions, MD simulations on the
PDE9Q453E-BAY73-6691 complex reached equilibration with
an average RMSD of 2.1 A ˚. In the simulated model, the pyrazolo-
pyrimidine ring of (S)-BAY73-6691 stacked against Phe456, in
agreement with that of the crystal structure. However, two key
distances between OE1 of Glu453 and N5 of (S)-BAY73-6691,
and between OE2 of Glu453 and OE1 of Glu406 were 5.3 and
4.2 A ˚, respectively, in contrast to 2.9 and 3.2 A ˚ in the crystal
structure of the PDE9Q453E mutant. Since 3.2 A ˚ represents the
distance of a hydrogen bond and no proton is expected to associate
with OE2 of Glu453 and OE1 of Glu406 under the crystallization
pH 7.5, a possible assumption might be that Glu406 in the
PDE9Q453E mutant locally sequesters a hydrogen atom and thus
exists in the protonated form. To test this hypothesis, a new model
with protonated Glu406 was subjected to MD simulations under
the same conditions (Fig. S2). In this MD simulation model, the
pyrazolo-pyrimidine ring of (S)-BAY73-6691 stacks against
Phe456 (Fig. 4); atom OE2 of Glu453 is in a hydrogen bond
distance (2.6 A ˚) to the protonated OE1 of Glu406 and 4.2 A ˚ to O4
of (S)-BAY73-6691; atom OE1of Glu453 forms a hydrogen bond
(2.9 A ˚) with N5 of (S)-BAY73-6691. Therefore, the new MD
simulations agree well with the crystal structure and suggest that
Glu406 in the crystal of the PDE9Q453E mutant likely exists in its
protonated form.
Discussion
The ‘‘glutamine switch’’ is unlikely the mechanism for
differentiation of substrates
An essential question about the PDE function is how PDE
molecules distinguish the two alternate substrates cAMP and
cGMP that show very subtle differences. An early proposal on the
substrate specificity, the ‘‘glutamine switch’’, is based on the crystal
structures of PDE4 and PDE5 in complex with their correspond-
ing reaction products [18]. In these structures, the side chain of the
invariant glutamine takes opposite orientations to form two
hydrogen bonds with AMP or GMP. The ‘‘glutamine switch’’
proposal assumes that the invariant glutamine in the dual specific
PDE families switches its side chain conformations to gain two
hydrogen bonds with different substrates. However, this hypothesis
was challenged by the observations that substrates cAMP and
cGMP have different orientations and interactions in the
structures of the dual specific PDE10 [20], and that cAMP forms
only one, but not two hydrogen bonds with cAMP-specific PDE4
[21]. In addition, the Q817A mutation in PDE5A reduces the
Table 2. Kinetic parameters of the catalytic domain of PDE9A2 and its mutants.
Enzymes cGMP cAMP
(kcat/KM)
cGMP
/(kcat/KM)
cAMP
KM (mM)
Vmax
(mmol/mg/min)
kcat
(S
21)K M (mM)
Vmax
(mmol/mg/min)
kcat
(S
21)
Wild type 0.11360.013 0.28560.008 0.1860.00 501643 3.7060.10 2.3760.06 337
Q453E 2.860.18 0.13960.003 0.0960.00 1233692 2.0360.07 1.3060.04 29
E406A 0.31160.04 0.12960.004 0.0860.00 338644 0.4860.02 0.3160.01 280
doi:10.1371/journal.pone.0018092.t002
Table 3. Effects of the mutations on IC50 of inhibitors.
Enzymes IBMX (mM) (S)-BAY73-6691 (nM) Zaprinast (mM)
Wild type 53.961.1 85.861.0 15.961.2
Q453E 117.261.2 (164.261.2)610
3 53.761.2
E406A 31.761.1 8261.1 7.661.1
doi:10.1371/journal.pone.0018092.t003
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kinetic behavior [19]. Since the replacement of hydrophilic
glutamine with hydrophobic alanine may cause relatively large
changes, we performed the Q453E mutation to eliminate the effect
of the side chain rotation of Gln453.
Our studies provide further evidence against the ‘‘glutamine
switch’’ mechanism. First, on the basis of the crystal structure of
PDE9-cGMP [22], the Q453E mutation would be predicted to
reduce the cGMP activity, but not to impact the cAMP activity
because the Q453E mutation will lead to loss of a hydrogen bond
with cGMP but no change with cAMP. However, our kinetic data
showed a 4.5-fold loss of the cAMP catalytic efficacy by the Q453E
mutant (Table 2), implying that substrate recognition is not achieved
by the simple rotation of the glutamine side chain. Second, the
E406A mutation would allow the Gln453 side chain to rotate and to
potentially form two hydrogen bonds with cAMP. Thus, the E406A
mutation would be expected to increase the catalytic efficacy.
However, the kinetic data of the E406A mutant showed that the KM
for cAMP essentially remained at the same level and kcat decreased
significantly.Therefore,ourdatasuggestthatthe‘‘glutamineswitch’’
is unlikely to be the mechanism for differentiation of the substrates,
although the invariant glutamine is critical for binding of substrates
and inhibitors,asshown by25-and 1800-foldaffinity decrease of the
mutant for cGMP and (S)-BAY73-6691, respectively.
Conclusions
1. The binding of inhibitors IBMX and (S)-BAY73-6691 to the
PDE9Q453E mutant shows significant asymmetry and the M-
loop demonstrates the significant positional difference in the
dimer of the PDE9Q453E mutant.
2. The kinetics of the Q453E and E406A mutants suggest that the
side chain of Gln453 may not rotate and thus the ‘‘glutamine
switch’’ is unlikely to be the mechanism for the substrate
recognition by PDEs.
3. The MD simulations suggest that Glu406 may be protonated
in the PDE9Q453E mutant and thus is capable of forming a
hydrogen bond with Glu453. This may explain the unusual
proximity of two negatively charged oxygen atoms in the
crystal structure.
Supporting Information
Figure S1 Electron density for (A) IBMX in subunit A of
the PDE9AQ453E mutant, (B) IBMX in subunit B, (C)
Bay73-6691 in subunit A, and (D) Bay73-6691 in subunit
B. The (Fo – Fc) maps were calculated from the structures in
which the inhibitors were omitted, and contoured at 2.5 sigmas.
(TIF)
Figure S2 Variation of the key non-bonded distances
during simulation. (A) Distance change between O4 of (S)-
BAY73-6691 and NE2 of Gln453 (black), and N5 of (S)-BAY73-
6691 and OE1 of Gln453 (red) in the wildtype PDE9A2. (B)
Distance change between O4 of (S)-BAY73-6691 and OE2 of
Glu453 (black), N5 of (S)-BAY73-6691 and OE1 of Glu453 (red),
and OE2 of Glu453 and protonated OE1 (labeled as OEh) of
Glu406 (blue) in the PDE9Q453E mutant.
(TIF)
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Figure 4. Simulated binding of (S)-BAY73-6691 at the active site of the PDE9Q453E mutant. (A) Interactions in the MD simulation model.
The carboxyl group of Glu406 was treated as a protonated form (marked as OEh). (B) Superposition of the crystal structure of PDE9Q453E-(S)-BAY73-
6691 (green and yellow) over the MD simulation model (cyan and salmon). The marked distances come from the crystal structure.
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